Study Details Sample Clauses

Study Details. Academic year: 2023-2025 Study Cycle: ☐
1st cycle (Bachelor) ☐
2nd cycle (Master) ☐
State Examination ☐
PhD (Promotion) Subject area: Tap here to enter text.
Degree: Tap here to enter text.
Number of completed higher education study years (prior to mobility): Tap here to enter text.
Called hereafter „the participant“, on the other part, have agreed the Special Conditions and the annexes below which form an integral part of this agreement („the agreement“): Annex I Learning Agreement for Erasmus+ mobility for traineeships ▇▇▇▇▇ ▇▇ General conditions Shall be filled in by the International Office! ISCED code: _____________ The participant receives: ☐ a financial support from Erasmus+ EU funds ☐ a zero-grant ☐ a partial financial support from Erasmus+ EU funds ☐ Base amount for individual support for long-term physical mobility ☐ Base amount for individual support for short-term physical mobility ☐ Top-up amount for students and recent graduates with fewer opportunities on long-term mobility ☐ Top-up amount for students and recent graduates with fewer opportunities on short-term mobility ☐ Top-up amount for traineeships ☐ Green travel top-up ☐ Travel support (standard travel or green travel amount) ☐ Travel days (additional individual support days) ☐ Exceptional cost for expensive travel (based on real costs) ☐ Inclusion support (based on real costs)

Study Details. Select your degree programme and intended degree from the drop-down menus. If your degree programme is missing from the list, please inform us asap. 〉 Internship Details Please provide as much information as possible about the internship position (ideally including the legal form of the company). Completion of Personal Details + Application and Internship data 4 〉 Details of Home Address Please enter your registration address here, i.e. the address on your identity card or residence permit. Please enter a telephone number (landline) and a mobile number. If you do not use a landline, please enter your mobile number in both fields.

Study Details. Please outline, in terms that any non-expert would understand, what your research project is about, including what participants will be required to do. 10) Subject selection: Yes No NA Version No. Effective Date Page a) Will subjects from both genders be recruited? ☐ ☐ ☐ b) Number of subjects to be recruited globally c) Number of subjects to be recruited in India d) Number of subjects to be recruited at MNR-MC 11) Aim and Objectives of Study (i.e. what is the intention of the study, key research questions?) 12) Specify the primary research question/objective 13) Specify the secondary research questions/objectives 14) Scientific justification for the clinical trial? 15) What are the inclusion criteria? 16) What are the exclusion criteria? Version No. Effective Date Page 17) What criteria exist for withdrawing research participants prematurely? 18) Scientific justification for the clinical trial? 19) Brief Study Procedure & Investigations (paste Study Flow Chart table) 20) Anticipated risks to participants (what, when, how often). Such risks could include physical stress, emotional distress, perceived coercion e.g. lecturer interviewing own students. Detail the measures and considerations you have put in place to minimize these risks. 21) Will treatment be withheld from research participants as a result of taking part in the clinical trial? ☐ Yes ☐ No If Yes, please give details Version No. Effective Date Page 22) What procedures are in place to monitor the health of the research participants during the trial or when they are no longer involved in the trial? 23) What are the potential benefits for research participants? 24) Proposed start date and duration of study Estimated close date: Duration (months): 25) Research location and in what setting? 26) Forms of obtaining consent ☐ Audio only ☐ Paper only ☐ Assent ☐ Audio & Video ☐ AV & Paper ☐ 27) Clinical phase of study ☐ Pilot investigation ☐ Phase 1 ☐ Post-marketing surveillance ☐ Pivotal investigation ☐ Phase 2 ☐ BA-BE ☐ Pilot performance (IVD) ☐ Phase 3 ☐ Single center ☐ Pivotal performance (IVD) ☐ Phase 4 ☐ Multi center 28) Does the study involve investigations and/or interventions Yes No a) Self completion questionnaire ☐ ☐ b) Audio/video tape recording ☐ ☐ Version No. Effective Date Page

Study Details. The start date of the Study is: The Effective Date The completion date is: 30 November 2020

Study Details. This statistical analysis plan (SAP) covers the Phase II (Part B) of the study only. The Phase I safety run-in part (Part A) of the study is not covered in this SAP.

Study Details. The Partner programme will be delivered in English and assessed in English. The York St ▇▇▇▇ programme will be assessed in English. Application forms must be received by the Admissions Team at York St ▇▇▇▇ University, no later than six weeks prior to the expected date of transfer to York St ▇▇▇▇ University. Students wishing to enrol for programmes at York St ▇▇▇▇ University, other than those listed in this agreement are welcome to apply. Such applications will be considered on an individual basis This agreement is based on the current curriculum offered by York St ▇▇▇▇ University. The University will inform the Partner about any changes to its programmes relevant to the consequences of this agreement In the event of the Partner ceasing to trade, York St ▇▇▇▇ University will continue to accept students that have completed their studies and have met the conditions of entry specified in this Articulation Agreement The University will undertake to review and feedback on the Partner’s proposed marketing materials within two weeks of receipt. The Partner will ensure that its portfolio of programmes has all the necessary regulatory and statutory authority to operate and that any terms or conditions required are met in full. The Partner will be responsible for the recruitment and recommendation of students to the University. The Partner will provide the Admissions team at York St ▇▇▇▇ University with a full transcript of results for all students applying to York St ▇▇▇▇ University as soon as results are confirmed. This agreement is based on the current curriculum offered by the Partner. Any changes made by the Partner will be notified to York St ▇▇▇▇ University in advance of the changes. This may result in a suspension of this agreement until the new curriculum has been reviewed and approved by the University. If changes occur without notification, this agreement will be terminated. The Partner is responsible for informing their students about any changes and their consequences for this agreement. The Partner shall inform the University immediately of any change of ownership or governance at the Partner Institution. The University reserves the right to re-negotiate any collaborative agreement if there is a change of ownership of governance of the Partner institution. The Partner will submit marketing materials to the University for approval a minimum of six weeks before they are due to be published. On admission to York St ▇▇▇▇ University, students will be subject...

Study Details. The precise location(s) of the trial site(s) and related plots are yet to be determined and will be confirmed by the Steering Committee. The EUP trial design is divided into two study designs (Trial A and Trial B). These may take place simultaneously or in sequence as decided by the Steering Committee. The objectives of the Field Trial A will be to quantify various parameters from a single release point. Site selection will be based on specific criteria. All sites will comply with the following criteria: • Total study area: minimum of 25 and maximum of 200 acres. These areas are based on the expected distribution of male Aedes aegypti from a single release point. For example, if the maximum distance travelled is ~180 m, that equates to a circle with an area of 25 acres based around a single mosquito release point. If the maximum distance travelled is ~500 m, that equates to a circle with an area of 200 acres based around a single mosquito release point. Most studies have found the maximal distance travelled by wild Aedes to be between 82 and 400m, this being heavily influenced by climatic conditions, presence of vegetation and the availability of breeding sites (▇▇▇▇▇▇ et al., 1995; ▇▇▇▇ & ▇▇▇, 1998; ▇▇▇▇▇▇▇ et al., 2005). Previous field releases of OX5034 male mosquitoes in Brazil have recorded maximum dispersal distances of 198 m. • As requested by EPA, trial areas will be separated by at least 500m and if mosquitoes are trapped at the perimeter of a Trial A area, then additional ovitraps will be installed at distances greater than 400 m from the release site to capture any mosquitoes that may travel further. These additional traps may be constrained in terms of direction by available land mass, although every effort will be made to accommodate the distances required. Water bodies such as canals or ponds up to approximately 100m across will be considered not to impact dispersal. • Confirmed presence of Aedes aegypti (based on surveillance data). • Available documentation of mosquito abatement (other than experimental treatment) during the period of study. Treated and untreated areas of the EUP will be chosen to be as similar as possible, including in terms of any known mosquito abatement activity. • The outer boundary of the trial area (denoted by the traps furthest from the central release point) will be greater than 500 m from commercial citrus growing areas and from sewage treatment plants. Figure 1. Schematic overview of a trial site for Trial A show...